New trial aims to outsmart drug resistance in colorectal cancer
NCT ID NCT07318389
First seen Jan 09, 2026 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This early-phase trial tests whether matching drug combinations to a patient's tumor characteristics can better control metastatic colorectal cancer. Researchers will use blood draws, biopsies, and imaging to track how tumors resist treatment. The study enrolls 100 adults with measurable tumors and aims to check safety first.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Combination of standard chemotherapy (FOLFIRI, FOLFOX) and targeted drugs (bevacizumab, cetuximab, panitumumab, encorafenib, adagrasib, trifluridine/tipiracil, trastuzumab deruxtecan, tucatinib, sotorasib) chosen based on tumor genetics
What this could lead to
If successful, this could point toward more effective, personalized treatment plans for metastatic colorectal cancer by overcoming drug resistance.
What could go wrong
This is a very early (Phase 1) trial with only 100 participants, so results may not apply broadly. The main goal is safety, not yet proof of effectiveness. Side effects from multiple drug combinations are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.